title: Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
authors.affiliation: Sections of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy. francodam@dimo.uniba.it
authors.forename: Franco
authors.initials: F
authors.lastname: Dammacco
authors.forename: Felicia Anna
authors.initials: FA
authors.lastname: Tucci
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Lauletta
authors.forename: Pietro
authors.initials: P
authors.lastname: Gatti
authors.forename: Valli
authors.initials: V
authors.lastname: De Re
authors.forename: Vincenza
authors.initials: V
authors.lastname: Conteduca
authors.forename: Silvia
authors.initials: S
authors.lastname: Sansonno
authors.forename: Sabino
authors.initials: S
authors.lastname: Russi
authors.forename: Maria Addolorata
authors.initials: MA
authors.lastname: Mariggiò
authors.forename: Maria
authors.initials: M
authors.lastname: Chironna
authors.forename: Domenico
authors.initials: D
authors.lastname: Sansonno
mesh_terms: D000368:Aged; D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000276:immunology; D001483:Base Sequence; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D017931:DNA Primers / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D050438:Genes, Immunoglobulin Heavy Chain; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008099:Liver / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011379:Prognosis; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012074:Remission Induction; D012254:Ribavirin / Q000008:administration & dosage*; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D017931:DNA Primers; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000069283:Rituximab; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a